Abstract
needed to increase the cure rate. In vitro experiments show strong antiviral effects of fluvastatin against HCV. Aim of the study: To asses the clinical outcome of fluvastatin addition to the standard regimen for treatment of chronic HCV in Egypt. Subjects and Methods: The study included 80 patients with chronic hepatitis C virus infection fulfilled clinical, laboratory and histo-pathological criteria to be ready for interferon therapy, divided into two groups: Group I (n = 40) received standard treatment for HCV (pegylated interferon and ribavirin) and group II (n = 40) received standard treatment plus fluvastatin (80mg/daily). Before and after 6 months of treatment liver function tests and HCV-RNA were evaluated. Results: Addition of fluvastatin to the standard HCV treatment (pegylated interferon and ribavirin) significantly increased SVR from (55% to 62.5%; P< 0.01) and significantly decreased viral load in relapser patients (P< 0.001). No significant differences and correlations were found between serum levels of LDL-cholesterol and viral load before and after treatment in both groups. Conclusion: Fluvastatin can be used to increase SVR when added to standard treatment (pegylated interferon and ribavirin) of chronic HCV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
